Eli Lilly and Company LLY
NYSE · Healthcare · Drug Manufacturers - General
$1,347.11
Close on Fri, 20 Nov 2026 · market value $1.3T
What the price is betting on
In line with its recordAt $1,347, the price assumes revenue grows about 17% a year for four years, from $86.5B to about $148B by FY2029. That is about one and a half times what analysts expect and less than the company's own last three years.
Revenue growth a year. The price figure comes from a reverse DCF at a 7.2% discount rate.
Track it and Parra checks each report against the path, and tells you when revenue falls behind it.
Own more than LLY? Check up to 5 of your stocks at once, free, no account.
Both sides
Three stories, three values
Bear
$651
Base
$1,004
Bull
$1,840
Today $1,347
- Bear $651. The demand surge fades after about two years as payers push back on obesity and diabetes drug prices and cheaper rival pills take share. Oncology and immunology are too small and slow to replace the lost growth because one franchise is most of revenue. The factory build-out proves larger than the growth that follows, so cash flow margins settle below today's upkeep-only level.
- Base $1,004. Lilly's revenue grows about as analysts forecast, fastest next year and slower in each of the four years they cover, then fades to a long-run pace. Margins stay near today's very high level and factory spending eases once growth cools. Pricing pressure and rival obesity pills slow the path but do not break it.
- Bull $1,840. Lilly grows faster than analysts forecast and stays high for about six years. Demand for the diabetes and obesity franchise holds despite pricing pressure, and neuroscience growth, the wider cardiovascular label and pipeline and partnership news begin to widen the base beyond one franchise. Top-tier margins hold as the build-out matures, so cash flow catches up with earnings.
AI-written stories, valued by code from the same model.
Checkpoints
The revenue the price needs
- YearNeedsAnalysts expect
- FY2026$91.2B$91.3B, on the path
- FY2027$111B$107B, below the path
- FY2028$130B$119B, below the path
- FY2029$148B$131B, below the path
Each year's revenue at 17% growth from $86.5B in the 12 months to September 2026.
At a glance
Healthcare · Drug Manufacturers - General · listed on NYSE
- Revenue, FY2025
- $65.2B
- Growth, 3 years a year
- 40%
- Cash margin
- 14%
- Net debt
- $35.2B
- Shares, 3-year change
- −0.7%
- Dividend yield
- 0.4%
What other healthcare prices are betting on
Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.